4/17
03:26 pm
clnn
Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
4/16
05:26 pm
clnn
Clene stock rallies 52% post-market on MS drug data [Seeking Alpha]
High
Report
Clene stock rallies 52% post-market on MS drug data [Seeking Alpha]
4/16
04:19 pm
clnn
Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting [Yahoo! Finance]
High
Report
Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting [Yahoo! Finance]
4/16
04:01 pm
clnn
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Medium
Report
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
3/20
08:32 am
clnn
Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $5.00 price target on the stock.
Low
Report
Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $5.00 price target on the stock.
3/19
08:45 am
clnn
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington [Yahoo! Finance]
Low
Report
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington [Yahoo! Finance]
3/19
08:30 am
clnn
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
Medium
Report
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
3/18
03:11 pm
clnn
Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
3/15
08:23 am
clnn
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® [Yahoo! Finance]
Low
Report
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® [Yahoo! Finance]
3/15
08:00 am
clnn
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
Medium
Report
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
3/13
08:12 am
clnn
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights [Yahoo! Finance]
Medium
Report
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights [Yahoo! Finance]
3/13
08:00 am
clnn
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Medium
Report
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
3/7
08:08 am
clnn
Clene to Present at the 36th Annual ROTH Conference [Yahoo! Finance]
Low
Report
Clene to Present at the 36th Annual ROTH Conference [Yahoo! Finance]
3/7
08:00 am
clnn
Clene to Present at the 36th Annual ROTH Conference
Low
Report
Clene to Present at the 36th Annual ROTH Conference
2/29
08:14 am
clnn
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024 [Yahoo! Finance]
Medium
Report
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024 [Yahoo! Finance]
2/29
08:00 am
clnn
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
High
Report
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
2/22
12:31 pm
clnn
Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
2/22
08:09 am
clnn
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs [Yahoo! Finance]
Low
Report
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs [Yahoo! Finance]
2/22
08:00 am
clnn
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
High
Report
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
2/5
02:44 pm
clnn
Clene Inc. announces positive results from CNM-Au8 results from MS trial [Yahoo! Finance]
Medium
Report
Clene Inc. announces positive results from CNM-Au8 results from MS trial [Yahoo! Finance]
1/24
08:54 am
clnn
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment [Yahoo! Finance]
Medium
Report
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment [Yahoo! Finance]